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Expression and regulation of 
drug transporters in vertebrate 
neutrophils
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Catherine A. Loynes1,3, Phil Jeffrey6, Angeleen Fleming7,8, Caroline O. Savage5, Annemarie H. 
Meijer4, Simon Jones2 & Stephen A. Renshaw  1,3
There remains a need to identify novel pro-resolution drugs for treatment of inflammatory disease. 
To date, there are no neutrophil-specific anti-inflammatory treatments in clinical use, perhaps due 
to our lack of understanding of how drugs access this complex cell type. Here we present the first 
comprehensive description and expression of both major classes of drug transporters, SLC and ABC, 
in resting human blood neutrophils. Moreover, we have studied the expression of these carriers in 
the tractable model system, the zebrafish (Danio rerio), additionally examining the evolutionary 
relationship between drug transporters in zebrafish and humans. We anticipate that this will be a 
valuable resource to the field of inflammation biology and will be an important asset in future anti-
inflammatory drug design.
New treatment approaches are urgently needed for inflammatory diseases in which inflammation fails to resolve 
spontaneously, for example Chronic Obstructive Pulmonary Disease (COPD). Key innate immune cells, par-
ticularly neutrophils, are recruited to the affected organs in response to tissue damage or infection and may 
be retained there by proinflammatory signalling. These unwanted neutrophils can contribute to tissue damage 
and their removal is an important aim of anti-inflammatory therapy1. To date, there are no neutrophil-specific 
anti-inflammatory treatments in clinical use. Barriers to targeting this key cell include our lack of understanding 
of drug delivery into neutrophils and a lack of drug-screening assays with physiological readouts.
Zebrafish (Danio rerio) are an especially useful model organism in which to study neutrophil behaviour2, 
allowing genetic manipulation and subsequent in vivo imaging of the inflammatory process. The small size and 
large numbers of larvae produced in a single mating allow drug libraries to be screened efficiently. Drug screen-
ing approaches are routinely used by zebrafish groups around the world and have resulted in the identification of 
several neutrophil-targeted compounds3–6.
Knowledge of the mechanisms by which drug-like molecules enter neutrophils is important for the design of 
pharmaceuticals to modulate neutrophil function, both for improved drug screening strategies and for improved 
clinical outcome. Within the last twenty years, it has become clear that drug transporters (proteins that transport 
exogenous compounds across the cellular membrane) are crucial for absorption, distribution and excretion of 
exogenous compounds7, 8. No study has examined drug transporter expression in either neutrophils or zebrafish 
to date.
Drug transporters comprise two main families: solute carrier (SLC) and ATP-binding cassette (ABC) trans-
porters. In humans, there are 396 members of the SLC family and 51 members of the ABC family, according to 
the HUGO Gene Nomenclature Committee (HGNC) database (April 2015)9, and these exist for the transport of 
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metabolites and ions into and out of cells10. Indeed, the metabolite-likeness of many drugs in clinical use is highly 
supportive of the role of these transporters in the movement of therapeutic compounds across cell membranes11.
SLC transporters are considered responsible for the influx of molecules into the cell. In the same way, as one 
drug may act upon many target proteins, one drug may be transported by multiple transporters, thus making the 
identification of the transporters responsible for the entry of each compound challenging. The clearest example 
of drug transport by a SLC protein is perhaps in the treatment of pancreatic cancer with gemcitabine, which is 
predominantly transported by the SLC29A1 transporter (previously known as ENT1)12, 13.
ABC transporters are generally considered to be responsible for efflux of compounds from the cell, and first 
came to the attention of the pharmacokinetics field when it was noted that in patients carrying particular muta-
tions in ABC proteins, some drugs presented toxicity issues14, 15. Clearly, it is important to consider both influx 
and efflux of potentially therapeutic compounds during drug discovery and development.
Despite drug transporter expression being determined in humans and other animal models16, 17, to our sur-
prise, we were unable to identify either a published analysis of drug penetration into neutrophils or a descrip-
tion of drug transporter expression in neutrophils. In our hands, predicting efficacy and effective doses of drugs 
against neutrophils has been difficult both in vitro and in vivo4, 18–20. We therefore hypothesised that drug entry 
into neutrophils might be dependent on the differential expression and regulation of drug transporters, with 
important consequences for screening methodologies and rational anti-inflammatory drug design.
Here we present, to the best of our knowledge, the first comprehensive analysis of expression data of the SLC 
and ABC drug transporter families in both human and zebrafish neutrophils. Our analysis has also allowed for 
the identification of several previously unannotated SLC and ABC paralogues in zebrafish. These data are an 
important advance in both the neutrophil and zebrafish fields and may be useful in designing novel successful 
compounds for drug screening experiments and, ultimately, the treatment of inflammatory disease.
Results
Distinct subsets of transporter proteins are expressed and regulated in primary human neutro-
phils. To characterise the expression and regulation of transporter proteins in human neutrophils, we interro-
gated the best publicly-available RNAseq dataset from human neutrophils21. Initially we examined the SLC family, 
which are thought to be responsible for drug influx, and identified all members expressed in neutrophils. These 
are shown as a phylogenetic tree to allow visualisation of the evolutionary relationships between the members 
of transporter protein families in humans (Fig. 1, Supplementary Fig. S1). In primary human neutrophils, 134 
of the 389 SLC protein-coding family members (34%) were expressed. In the presence of the best characterised 
neutrophil survival factor, granulocyte macrophage colony-stimulating factor (GM-CSF), nine genes were signif-
icantly regulated, all of which were expressed in primary human neutrophils. Of these genes, two of nine (SLC1A5 
and SLC25A25) were up-regulated, whilst the remaining seven genes (SLC10A3, SLC15A3, SLC15A4, SLC16A14, 
SLC16A6, SLC19A1 and SLC25A51) were down-regulated. In the presence of tumor necrosis factor alpha (TNFα), 
Figure 1. Subsets of SLC transporter proteins are expressed and regulated in primary human neutrophils. 
Scalable phylogenetic trees in both (a) circular and (b) unrooted display modes indicate evolutionary 
relationships between SLC transporter proteins in humans (branch lengths are not proportional to genetic 
distance; see Supplementary Fig. S1 for trees with proportional branch lengths). In (a), for primary human 
neutrophil expression data (inner circle), expressed proteins are marked with a black dot, whereas proteins 
not expressed are denoted with a white dot. For GM-CSF (second circle from centre) and TNFα (third circle 
from centre) regulation data, significant up-regulation of a gene is denoted with a green box, significant down-
regulation is denoted by a red box, and a lack of significant change in regulation is unmarked. For human 
neutrophil proteomics data (outer circle), any proteins identified in one or more of the analyses are denoted 
with a blue box, and any not identified are denoted with a white box.
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another key regulator of neutrophil function, the expression of six genes was significantly up-regulated. Of these, 
three were expressed in unstimulated primary human neutrophils (SLC1A5, SLC35B2 and SLC7A5), whilst three 
were not expressed (SLC11A2, SLC2A6 and SLC30A4). No genes were found to be significantly down-regulated. 
The regulation of just one gene, SLC1A5, was significantly affected by GM-CSF and TNFα, being up-regulated 
by both mediators. Whilst SLC1A5 (also known as Alanine Serine Cysteine Transporter 2, ASCT2) is a neutral 
amino acid transporter with ubiquitous expression, overexpression of this gene has been discovered in various 
cancers22, 23, and it is currently being explored as a possible drug target for cancer treatment24. To extend these 
studies, we carried out an analysis of the SLC transporter proteins identified in any of eight publicly available 
human neutrophil proteomics studies25–32. In these datasets, a total of 33 SLC transporter proteins were identified, 
of which we had identified 20 as being expressed based on RNAseq data, highlighting the incomplete nature of 
current proteomic datasets and the differences between gene and protein expression in neutrophils. In general, 
our data indicate significant potential for differential sensitivity of activated neutrophils to different drug classes 
and should be considered as part of anti-inflammatory drug design.
The ABC transporter family is considered to be responsible for drug efflux. A parallel analysis of this family 
was performed and displayed as a phylogenetic tree in the same way as for the SLC family (Fig. 2, Supplementary 
Fig. S2). In primary human neutrophils, 17 out of 48 ABC protein-coding family members (35%) were expressed. 
Interestingly, in contrast to the SLC transporters, none of the ABC transporters were significantly up- or 
down-regulated in the presence of either GM-CSF or TNFα. This perhaps suggests that the SLC transporters may 
have a specific role in regulation of neutrophil function in response to these key mediators. Across the various 
human neutrophil proteomics studies, 6 ABC transporter proteins were identified, 3 of which we identified as 
being expressed in primary human neutrophils based on RNAseq data.
In order to validate our approach and the quality of the dataset, we also performed the same unstimulated 
expression analysis on a second human neutrophil RNAseq dataset33. This analysis showed a highly significant 
positive correlation between the two datasets for both the SLC transporters (r = 0.9157, P < 0.0001) and the ABC 
transporters (r = 0.8368, P < 0.0001) (Fig. 3, Supplementary Tables S3 and S4), providing further confidence in 
our approach.
Anti-inflammatory compounds differentially accumulate in zebrafish. Our model of choice 
for the mechanistic dissection of neutrophil function is the zebrafish34. The small size of the larvae combined 
with the presence of functional innate immunity make this system highly suitable for drug screening for new 
anti-inflammatory molecules4, 5, 35. We have previously shown that the SGK1 inhibitor GSK650394 can induce 
apoptosis in human neutrophils in vitro, and in zebrafish inflammation models in vivo. Moreover, mass spec-
trometry analysis has shown that this compound is able to penetrate zebrafish larvae in order to exert its effect20. 
To examine the kinetics of drug penetration into zebrafish larvae, we performed a timecourse of compound 
administration and analysed the resulting concentrations by mass spectrometry. Accumulation of GSK650394 
in larvae was rapid reaching a plateau within an hour (Fig. 4a). Other groups have examined the ability of com-
pounds to penetrate zebrafish larvae36, 37, and reanalysis of published data reveals a marked dichotomy between 
compounds that are found inside zebrafish larvae at very low concentrations (<15% of external concentration) 
and compounds which are markedly concentrated within the larvae (>1000%, Fig. 4b). While high cLogP values 
Figure 2. Subsets of ABC transporter proteins are expressed but not regulated in primary human neutrophils. 
Scalable phylogenetic trees in both (a) circular and (b) unrooted display modes indicate evolutionary 
relationships between ABC transporter proteins in humans (branch lengths are not proportional to genetic 
distance; see Supplementary Fig. S2 for trees with proportional branch lengths). In (a), for primary human 
neutrophil expression data (inner circle), expressed proteins are marked with a black dot, whereas proteins 
not expressed are denoted with a white dot. For human neutrophil proteomics data (outer circle), any proteins 
identified in one or more of the analyses are denoted with a blue box, and any not identified are denoted with a 
white box.
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predicted concentration in larvae, for lower values there was no correlation. This suggested to us that active trans-
port mechanisms might be responsible for some of the differences between rapidly accumulated compounds and 
compounds excluded from the larvae.
Zebrafish neutrophils express a distinct subset of transporter proteins. To examine whether drug 
transporter expression and regulation might underlie the unpredictable nature of larval drug penetration, and to 
specifically relate this to the neutrophil, we used RNAseq datasets of neutrophils sorted from Tg(mpx:GFP)i114 
zebrafish at 5 days post fertilisation (dpf)38. From these datasets, we examined expression of transporter gene 
families. Zebrafish orthologues were identified by manually searching the Ensembl database for the orthologue 
of each human SLC and ABC gene. Furthermore, to ensure that all relevant zebrafish genes were included, the 
paralogous genes for each zebrafish orthologue were identified using Ensembl. These were then cross-referenced 
against our existing dataset, and any additional genes not yet in our dataset were added. Where it was unclear if a 
particular paralogue was a ‘true’ paralogue, the corresponding gene tree in Ensembl was examined. If a paralogue 
had a clear relationship to one or more annotated drug transporter genes in zebrafish, it was included in our data-
set. Any paralogues which could not be identified as having such a relationship, or which were clearly related to 
different protein families, were excluded from our analysis.
For the zebrafish SLC genes and their paralogues, a phylogenetic tree was constructed to display their ancestral 
relationships (Fig. 5, Supplementary Fig. 5). Of the 533 zebrafish protein-coding genes, 142 (27%) were expressed 
in zebrafish larvae neutrophils, whilst 219 (41%) were expressed in “background” (non-neutrophil) cells. 12 of 
the 142 genes expressed in neutrophils were expressed solely in neutrophils, and not in background cells: slc2a3b, 
Figure 3. Expression of human SLC and ABC transporter proteins across two different datasets shows 
highly significant positive correlation. Scattergraphs show comparison of expression of (a) SLC and (b) ABC 
transporter proteins in datasets by Wright et al. and Chatterjee et al.21, 33. Data points represent the mean of 
replicate values. Any genes in the Wright et al. dataset which could not be identified in the Chatterjee et al. 
dataset are not shown. For (a), r = 0.9157, P < 0.0001 (Spearman correlation, n = 368 pairs). For (b), r = 0.8368, 
P < 0.0001 (Spearman correlation, n = 47 pairs). Corresponding tables are provided in Supplementary Tables S3 
and S4.
Figure 4. Drug penetration into larvae is not entirely predicted by cLogP. (a) Amount of GSK650394 in 
zebrafish larvae was measured at the timepoints shown by mass spectrometry. (b) cLogP data from ref. 36 and 
the corresponding data for GSK650394 are shown plotted against fold enrichment of the compound in larvae 
compared to the concentration in surrounding liquid. Data are for larvae at 3 dpf incubated for 1 hour.
www.nature.com/scientificreports/
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slc2a8, slc2a12, slc2a15a, slc3a2_4of4, slc4a2b, slc13a1, slc13a5b, slc34a2b, slco3a1, rhcgl1, and CR352249.1. A 
further 130 genes were expressed in both neutrophil and background cells, whilst 89 genes were expressed in 
background cells yet not in neutrophils at this developmental stage.
Finally, a phylogenetic tree was produced to examine the ABC transporter family in zebrafish (Fig. 6, 
Supplementary Fig. 6). There are 64 protein-coding ABC transporter genes in total, of which 16 genes (25%) 
were found to be expressed in zebrafish neutrophils, and 17 genes (27%) were expressed in background cells. 
Of the 16 genes expressed in neutrophils, four were expressed in neutrophils alone: abca2, abcb4, abcb9, and 
si:dkey-57h18.2. In addition, 12 genes were expressed in both neutrophil and background cells, whilst five genes 
were expressed in non-neutrophils cells only.
Defined SLC and ABC drug transporters are conserved in human and zebrafish neutrophils. A 
more detailed analysis of available datasets revealed that the overall proportion of drug transporter proteins 
Figure 5. Zebrafish neutrophils and non-neutrophil cells express distinct subsets of SLC transporter proteins. 
Scalable phylogenetic trees in both (a) circular and (b) unrooted display modes indicate evolutionary 
relationships between SLC transporter proteins in zebrafish (branch lengths are not proportional to genetic 
distance; see Supplementary Fig. S5 for trees with proportional branch lengths). In (a), for both neutrophil 
(inner circle) and background cell (outer circle) expression data, expressed proteins are marked with a black 
box, whereas proteins not expressed are unmarked.
Figure 6. Zebrafish neutrophils and non-neutrophil cells express distinct subsets of ABC transporter 
proteins. Scalable phylogenetic trees in both (a) circular and (b) unrooted display modes indicate evolutionary 
relationships between ABC transporter proteins in zebrafish (branch lengths are not proportional to genetic 
distance; see Supplementary Fig. S6 for trees with proportional branch lengths). In (a), for both neutrophil 
(inner circle) and background cell (outer circle) expression data, expressed proteins are marked with a black 
box, whereas proteins not expressed are unmarked.
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expressed in neutrophils of each species was approximately equal (considering the various technical differences 
between the datasets). For the SLC family, 34% of human SLC genes were expressed in human neutrophils, com-
pared with 27% of zebrafish SLC genes expressed in zebrafish neutrophils. Similarly, for the ABC family, 35% of ABC 
genes in humans were expressed in neutrophils, compared to 25% expression in zebrafish neutrophils. In addition, 
in both human and zebrafish neutrophils, the median SLC and ABC expression values were roughly in line with the 
median expression level of all genes in the human and neutrophil datasets respectively. In humans, the median ‘frag-
ments per kilobase of exon per million fragments mapped’ (FPKM) values for SLC and ABC genes were 0.22 and 
0.34, compared with a median FPKM value of 0.26 for the entire set of genes. Likewise, in zebrafish neutrophils, the 
median FPKM values were 0.16 for SLC genes, 0.13 for ABC genes, and 0.10 for the entire gene set. Furthermore, we 
found that for the SLC drug transporters, around half of the genes expressed in primary human neutrophils (65 out 
of 134 genes, 49%) had at least one orthologous gene in zebrafish which was also expressed in zebrafish neutrophils 
(see Supplementary Table S7 for a full list of genes). In the set of ABC drug transporters, a similar proportion of the 
genes expressed in human neutrophils (eight out of 17 genes, 47%) had an orthologous gene also expressed in zebraf-
ish neutrophils (full list provided in Supplementary Table S8). When taken together, all these data suggest a level of 
conservation in SLC and ABC drug transporter expression between human and zebrafish neutrophils.
Discussion
The drug discovery process optimises the compound properties such that compounds can reach their target, act 
on it to have the desired therapeutic effect, and be metabolised and excreted in such a way as to avoid toxicity. This 
is crucial both for discovery science in animal models and for compounds that ultimately make it to the clinic. 
Large compound screens in zebrafish, whether of approved drugs, natural products, new chemical entities or 
tool compounds, have been highly successful (for a review of zebrafish drug screens see MacRae and Peterson39). 
However, a proportion of potentially valuable compounds or drug targets may be missed due to the “false nega-
tive” rate of these approaches40.
“False negatives” may occur due to the inherent biological variation of the experimental approach, solubility 
issues or the fact that the compound cannot reach its intracellular target. In the latter case, we suggest that differ-
ential drug transporter expression may hold the key to the failure of these compounds. In cases where drugs are 
toxic, one possible cause is that the drug (or its metabolites) is not actively removed from the cell. Drug trans-
porters (particularly ABC transporters) appear to be crucial in eliminating this source of toxicity, as shown by a 
reduced tolerance of patients with drug transporter mutations to some medications14, 15.
Drug transporters originate from two gene families, the SLC and ABC families, and are responsible for the 
transport of metabolites and ions. Drugs which are structurally similar to endogenous metabolites can hijack 
the corresponding transporters to gain entry to or exit from a cell. This idea has been described and evidence 
presented in the literature for around 20 years7, 41, 42, yet the importance of these drug transporters in the drug dis-
covery process is often neglected. This is largely due to the substantial number of transporters in the genome, the 
fact that in most cases multiple transporters are each able to transport several drugs8, and the limited knowledge 
of which transporters are utilised by a particular drug.
We propose that a more thorough understanding of drug transporter expression in the cell type, organ or 
animal of interest may go some way towards addressing the issue of compound entry into and exit from a cell, 
making drug screening an even more efficient approach to drug discovery. We have begun this process, by under-
taking a comprehensive analysis of drug transporter expression in the neutrophil. We have also explored expres-
sion in a model organism for immune-based in vivo compound screens, the zebrafish.
Using the human gene families of SLC and ABC transporters as a starting point, we probed a published dataset 
to assess transporter expression in primary human neutrophils21. This revealed expression of 134 (of 389) SLC 
transporters and 17 (of 48) ABC transporters in human neutrophils. Of these, two and three SLC transporters 
were up-regulated by GM-CSF and TNFα, respectively. One transporter, SLC1A5, was up-regulated by both stim-
uli. ABC transporter expression was not regulated by these stimuli in this dataset. Moreover, when we compared 
these expression data to those in a second dataset33, we found that the relative expression patterns were largely 
conserved, thereby validating our results.
In the zebrafish, we searched for the orthologues of the human gene family members and further analysed the 
paralogues yet to be assigned to the family by manual analysis of the gene trees present in Ensembl. This uncov-
ered a number of previously unannotated paralogues in both the zebrafish SLC and ABC transporter families. 
Probing of the RNAseq dataset from sorted zebrafish larval neutrophils (GFP positive) and background cells 
(GFP negative), revealed expression of 231 SLC transporters in zebrafish larvae, including 12 SLC transporters 
specifically in neutrophils. Of the smaller ABC family, 21 transporters were expressed in zebrafish larvae and 
four of these specifically in neutrophils. In addition, a general comparison of the human and zebrafish larvae 
expression data using our chosen cut-off values indicated that the proportion of SLC and ABC transporter genes 
expressed in neutrophils was broadly conserved between species. However, it should be considered that these 
data correspond to zebrafish larvae at an early stage of development (5 dpf), and that such expression is likely to 
change as the zebrafish mature.
In neutrophils, mRNA expression and protein expression may not always correlate. Neutrophils must act 
rapidly to kill infectious threats and their arsenal must be preformed. Thus, many highly abundant proteins might 
not be expressed at mRNA level in mature neutrophils31. While the two human neutrophil RNAseq datasets that 
we have probed are largely consistent, a summary by Tomazella et al.25 demonstrated that human neutrophil 
proteomic datasets are highly variable among samples25. In addition, in both the human and zebrafish datasets, 
we have studied resting, rather than inflammatory, neutrophils. In the human dataset, some transporters show 
regulation in the presence of an inflammatory stimulus, suggesting that transporter expression may be modified 
in inflammatory states. However, extracting neutrophils from inflammatory sites is technically complex, particu-
larly in zebrafish. Such neutrophil asynchrony and plasticity, including their ability to release granule contents at 
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the cell surface promptly by exocytosis, endocytosis, proteolysis and ectosome formation, are important consid-
erations here, and have been reviewed extensively elsewhere43–46.
Here, we present RNA expression data alongside phylogenetic analysis which we hope will be easy to navigate 
and prove to be an important resource for the field. The key to now using this tool to improve the drug discov-
ery process is to understand which metabolites use which SLC and ABC transporters, and in turn to use this 
knowledge to inform compound design to more closely mimic metabolites, where possible. In silico comparison 
of drugs and their metabolite-likenesses would help to form hypotheses of potential transporters which could 
be tested in the zebrafish model. One possible experimental approach would be to knock out a family of SLC 
transporters using CRISPR/Cas9 genome editing, and then assess the effect of this on drug penetration into neu-
trophils or zebrafish larvae using a well-defined phenotypic readout. There is not currently a model system for 
rational dissection of drug transporters and their effects on inflammation, but we anticipate that this resource will 
provide the first step towards building such a system in vivo.
These are not small tasks, but will be hugely beneficial to those using zebrafish and neutrophils for drug 
discovery. We believe the genetic tractability, ready accessibility to externally-added compounds, and range of 
transgenic and biological assays of the zebrafish provide an ideal model for the molecular dissection of drug 
transporter biology in vivo.
Methods
Phylogenetic analysis. Lists of the SLC and ABC transporter genes found in humans were obtained from 
the HGNC database (April 2015)9. The Ensembl database (human data: version GRCh38.p2, release 79; zebrafish 
data: version Zv9, release 79)47 was searched manually for each human SLC and ABC gene identifier, and orthol-
ogous genes present in the zebrafish (Danio rerio) database (version Zv9, release 79) were identified. Due to some 
observed discrepancies in the naming of the zebrafish orthologues (for example, where two different genes had 
identical names in the database), the unique numerical identifier (for example, ENSDARG00000000001) was used 
to search for orthologues in each case, to avoid ambiguity. Gene names as returned from Ensembl were generally 
retained for all further analysis. Genes with identical names were arbitrarily given suffixes of _first and _second to 
enable distinction. Where genes were identified as being a ‘novel gene’ in the Ensembl database with no additional 
annotation, the corresponding name for the same gene was obtained from an earlier release of the same version of 
Ensembl (version Zv9, release 75) in accordance with the RNAseq data used (under accession number GSE78954).
In both human and zebrafish datasets, for each individual gene the longest corresponding protein-coding 
sequence was obtained from the Ensembl database. Any genes which were found not to code for proteins were 
then excluded from the analysis. Regulatory genes and pseudogenes were also excluded. Files containing protein 
sequence data used in this work can be accessed at The University of Sheffield Research Data Catalogue and 
Repository, ORDA (https://sheffield.figshare.com).
Clustal Omega (version 1.2.3) was used for multiple sequence alignment of protein sequences48, 49. The 
‘Phylogenetic Tree’ output (.ph file) was converted to Newick format using the Phylogeny.fr resource50. The latter 
format was inputted into the Interactive Tree of Life (iTOL) programme (version 3.3) to produce phylogenetic 
trees displaying the evolutionary relationships in the human and zebrafish SLC and ABC families51. The phyloge-
netic trees were then annotated with the corresponding expression and proteomics data.
Expression and regulation of human transporter proteins. Published transcriptomics datasets 
(accessed via the NCBI Gene Expression Omnibus (GEO), accession number GSE4054821) were downloaded 
and used for analysis. In these data, RNA from 3 different neutrophil donors was analysed, isolated from 3 × 107 
neutrophils, and in all cases RNA integrity was ≥8.0. A gene was herein defined as being expressed if it had a 
FPKM value greater than or equal to 1, a conservative value chosen due to its relationship to expression of mye-
loperoxidase (MPO) - a well-validated neutrophil protein (expression level 0.98 FKPM). Any gene with a FPKM 
value less than 1 was defined as unexpressed. Human neutrophil proteomics data from 8 different studies were 
manually searched for any SLC and ABC transporter proteins identified therein25–32. For expression validation, 
each SLC and ABC gene was searched for in the dataset generated by Chatterjee et al. (4 donors, median RNA 
integrity 8.05) (accession number GSE59528)33, and mean FPKM values were plotted against the corresponding 
data from Wright et al. (following logarithmic transformation of both datasets)21. All human genes and proteins 
are referred to according to HGNC conventions throughout. Raw data files used to generate figures in this work 
can be accessed at ORDA.
Expression and regulation of zebrafish transporter proteins. Cells from zebrafish larvae 
(Tg(mpx:GFPi114), 5 dpf) were sorted into GFP-positive (neutrophils) and GFP-negative (background) cell pop-
ulations and RNAseq analysis performed, as described previously38 (data deposited on GEO under accession 
number GSE78954). Each experiment was performed in duplicate. For both neutrophil and background cell 
expression levels, we define any gene with a FPKM value greater than or equal to 1 as being expressed, and any 
with a FPKM value less than 1 as being unexpressed, in line with the definitions used for expression of human 
genes. All zebrafish genes and proteins are hereby referred to in accordance with the Zebrafish Model Organism 
Database (ZFIN) naming conventions as far as practicably possible. Raw data files used to generate figures in this 
work can be accessed at ORDA.
Mass Spectrometric analysis. Frozen 3 dpf zebrafish samples (20 fish per time point) were defrosted at 
room temperature on the day of analysis and diluted by the addition of 500 µL water. Each sample was then 
homogenised using a Soniprep 150 to disrupt the tissue with 3 × 10 s sonication bursts. Samples were subse-
quently processed then analysed by LC-MS/MS using an API 4000 triple quadrupole mass spectrometer (AB 
Sciex), as previously described20.
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